Pharma's Computational Arms Race Heats Up as Bristol Myers Squibb Builds Supercomputing Drug Discovery Powerhouse
Bristol Myers Squibb partners with Nvidia to deploy what it claims will be the life sciences industry's most powerful AI infrastructure, signaling an escalating battle for computational supremacy in drug development.
Diagnostic Giant Labcorp Enters AI Drug Discovery Race With Decades of Patient Data as Secret Weapon
Laboratory testing leader leverages billions of clinical test results spanning years to challenge specialized AI drug discovery firms and reshape pharmaceutical research.
AI Pathology Giants Unite: How Eight Companies Plan to Reshape Drug Development from the Inside
South Korea's Lunit joins global consortium targeting the pharmaceutical value chain with AI-powered biomarker discovery and patient selection technologies.
Nobel Winner's 100-Person Lab Tackles AI Protein Design's Billion-Dollar Manufacturing Problem
David Baker's University of Washington team can now computationally design full antibodies from scratch, but translating digital proteins into stable drugs remains the industry's defining challenge.
OpenAI Loses Another AI Scientist to Booming Drug Discovery Gold Rush as Researcher Eyes $2 Billion Valuation
Miles Wang's departure to launch an AI-powered drug repurposing startup highlights the accelerating exodus of talent from general AI labs to specialized healthcare ventures.
AI Drug Discovery Firm Lands Second $177M Deal in 90 Days as Platform Monetization Accelerates
Insilico Medicine's rapid-fire partnerships with China Medical System signal a pivotal shift from AI platform development to commercial-stage drug discovery, with CNS target identified entirely by generative algorithms.
Big Tech's Billion-Dollar Blind Spot: Why AI Giants May Stumble in the Drug Development Race
Anthropic joins the pharma AI rush, but industry insiders warn that cracking molecular codes is the easy part—surviving clinical trials demands data these companies don't have.
Big Pharma Bets Big on AI: Takeda Partners with Insilico to Reinvent Drug Discovery Pipeline
Major pharmaceutical company taps generative AI platform to slash development timelines and identify novel drug candidates across multiple therapeutic areas.
RNA-Targeting Breakthrough: Ionis Scores Dual Wins with First-Ever FCS Therapy and $430M Licensing Deal
FDA approval of Tryngolza for ultra-rare pancreatitis disorder and major partnership for hereditary angioedema treatment signal growing confidence in antisense oligonucleotide technology.
Why the FDA Is Betting on Biology-Driven AI to Fix Drug Development's $2 Billion Failure Problem
Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.
Pharma Giant Bets Half a Billion on Chip-Based Antibody Platform That Could Revolutionize Drug Hunting
Merck commits up to $510 million in milestone payments to Protillion Biosciences for AI-powered antibody discovery using on-chip screening technology.
Recursion Pharmaceuticals Advances Three AI-Discovered Drug Candidates Into Phase 2 Trials
Recursion Pharmaceuticals has announced that three drug candidates identified through its AI-powered drug discovery platform have advanced into Phase 2 clinical trials, marking a significant milestone for the AI-native pharmaceutical development model.